RESUMO
In this article, the GEITDAH -the Spanish abbreviation of the Special Interest Group on Attention Deficit Hyper-activity Disorder (ADHD)- presents a consensus reached by experts in the management of ADHD from all over Spain. The consensus concerns fundamental aspects that should be the starting point for future local or regional consensus guides. Another aim of this consensus is also to reduce the amount of variability that occurs in the health care offered to patients with ADHD in our country, as well as to act as a stimulus in educational matters. That fact that it is not very long will make it more popular among greater numbers of people and this will allow these goals to be reached more effectively. The conclusions in the consensus guide have been constructed around an introduction dealing with basic aspects and recommendations for diagnosis, treatment (both pharmacological and psychotherapeutic), patient flow and organisational aspects.
Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Consenso , Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico , Transtorno do Deficit de Atenção com Hiperatividade/terapia , Guias como Assunto , Humanos , Psicoterapia , EspanhaRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Criança , Programas de Rastreamento/história , Programas de Rastreamento/legislação & jurisprudência , Programas de Rastreamento/métodos , Atenção Primária à Saúde/métodos , Atenção Primária à Saúde/tendências , Transtorno Autístico/epidemiologia , Transtorno Autístico/terapia , Cuidado Pré-Natal/tendências , Diagnóstico Pré-Natal/métodos , Diagnóstico Pré-Natal/normas , Atenção Primária à Saúde/organização & administração , Atenção Primária à Saúde/estatística & dados numéricos , Transtorno AutísticoRESUMO
No disponible
No disponible
Assuntos
Humanos , Feminino , Criança , Bruxismo/complicações , Transtorno Obsessivo-Compulsivo/complicações , Sertralina/efeitos adversos , Buspirona/uso terapêutico , Fluoxetina/uso terapêutico , Paroxetina/uso terapêuticoRESUMO
OBJECTIVE: To study the clinical benefits and safety of paroxetine (PXT) in a group of patients younger than 14 years old, with a diagnosis of major depressive disorder. METHOD: Patients were recruited from a psychiatric outpatient clinic. They were assessed for disease severity using the Clinical Global Severity (CGS) scale at 1 month, 3 months, and 8 months. Intensity of the therapeutic response (the reduction in CGS) was measured after 1 and 3 months. All patients were given open-label treatment with PXT. RESULTS: At the start of treatment, most patients had "severe" depression (mean CGS score, 3.02). This improved to a score of 2.2 after 1 month and to 1.22 after 3 months of treatment. All patients experienced a complete remission of symptoms by the end of treatment (mean 8.4 months). PXT was well tolerated. Only 4 of the 45 patients experienced (mainly gastrointestinal) side effects; in 3 patients the side effects were of mild severity, and none required withdrawal from the trial. CONCLUSIONS: PXT can be effective in treating major depression and was well tolerated by children younger than 14 years old. This result indicates that PXT should be investigated further in children, in double-blind trials.
Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Paroxetina/uso terapêutico , Adolescente , Criança , Feminino , Humanos , MasculinoRESUMO
The XYY syndrome presents with a wide variation in the clinical features, both of the physical and behavioral nature. We report two new cases which illustrate this statement. The first case presented with aggressive behaviour and cryptorchidism. The second case was associated with pathological short height, pubertal delay and cardiac features (extrasystoles and short PR interval). We revise some of the aspects of XYY syndrome.
